Genetic clues to the causes of primary biliary cirrhosis!

Researchers find new risk regions associated with primary biliary cirrhosis

2012-09-10

(Press-News.org) Researchers have newly identified three genetic regions associated with primary biliary cirrhosis (PBC), the most common autoimmune liver disease, increasing the number of known regions associated with the disorder to 25.

The team used a DNA microchip, called Immunochip, to survey more thoroughly regions of the genome known to underlie other autoimmune diseases to discover if they play a role also in PBC susceptibility. By combining the results from this survey with details of gene activity from a database called ENCODE, they were able to identify which cells types are most likely to play a role in PBC.

PBC affects approximately one in every three thousand people in the UK, and one in a thousand women over the age of 40. Inflammation in the bile ducts blocks the flow of bile, damaging the liver cells and causing further inflammation and scarring, and in severe cases will result in the need for a liver transplant.

There is currently no cure for PBC, so treatment is focused on slowing down the progression of the disease and treating any symptoms or complications that may occur. The biological pathways underlying primary biliary cirrhosis are poorly understood, although autoimmunity, where the body attacks its own cells, is known to play a significant role.

"Previous genetic screens have identified 22 regions of the genome underlying PBC risk, and many of these are known to play a role in other autoimmune diseases, such as multiple sclerosis and type I diabetes," says Dr Carl Anderson, co-senior author from the Wellcome Trust Sanger Institute.

"Using the Immunochip we were able to perform a much more thorough screen of the genomic regions previously associated with other autoimmune diseases. This resulted in us identifying a further three regions involved in PBC risk and identifying additional independent signals within some of those we already knew about."

The advantage of Immunochip over genome-wide technologies is that it focuses only on regions of the genome known to be associated with an autoimmune disease and thus captures more of the genetic variation within these regions. Immunochip can therefore be used to more thoroughly test these key candidate genes for association to a whole-host of immune-related traits, and identify low frequency and rare genetic variants associated with disease that would likely be missed by a microarray that covers a broader range of genetic regions.

The researchers found five genomic regions with multiple independent signals associated with the disorder, with one small region on chromosome 3 harbouring four independent association signals. These findings suggest that densely genotyping or sequencing known disease regions will be a powerful approach for identifying additional genetic risk variants and for further elucidating the role of rare genetic variation in complex disease risk.

"This study has allowed us to better understand the genetic risk profile of PBC and, by comparing our results with similar studies of other autoimmune diseases, we hope to further characterise the genetic relationship between this group of clinically diverse but biologically related disorders" says Dr Richard Sandford, co-senior author from the University of Cambridge "Over the next few years we will be extending our studies to search for genetic variants that affect disease course and treatment response. We hope that our studies will have a clinical impact, either directly through a more personalized approach to treatment or indirectly by furthering our understanding of the biological pathways underlying PBC leading to new treatments."

The most associated genetic variant within the newly implicated TYK2 gene was a low-frequency variant previously associated with multiple sclerosis (MS) that changes the coding sequence of the gene. Previous studies in MS have shown that individuals that carry a single copy of this variant have significantly reduced TYK2 activity, suggesting that modulation of TYK2 activity might represent a new therapeutic approach for the treatment of PBC.

"This study is an example of how people with rare conditions like primary biliary cirrhosis can work together with scientists and physicians to find a path towards drug targets and treatments for these diseases," says Collette Thain, MBE, Chief Executive of the PBC Foundation. "Although this is just the beginning of a long road to finding the genetic basis of PBC, with each study we are moving closer and closer to finally understanding and tackling this disease."

### Notes to Editors Publication Details Jimmy Z. Liu, Mohamed A. Almarri et al 'Dense fine-mapping study identifies novel disease loci and implicates coding and non-coding variation in primary biliary cirrhosis risk' Published online in Nature Genetics on 9 September DOI: 10.1038/ng.2395

Funding

A full list of funding can be found in the paper

Participating Centres

A full list of participating centres can be found in the paper

Selected Websites

The mission of the University of Cambridge is to contribute to society through the pursuit of education, learning and research at the highest international levels of excellence. It admits the very best and brightest students, regardless of background, and offers one of the UK's most generous bursary schemes. The University of Cambridge's reputation for excellence is known internationally and reflects the scholastic achievements of its academics and students, as well as the world-class original research carried out by its staff. Some of the most significant scientific breakthroughs occurred at the University, including the splitting of the atom, invention of the jet engine and the discoveries of stem cells, plate tectonics, pulsars and the structure of DNA. From Isaac Newton to Stephen Hawking, the University has nurtured some of history's greatest minds and has produced more Nobel Prize winners than any other UK institution with over 80 laureates. http://www.cam.ac.uk

The Wellcome Trust Sanger Institute is one of the world's leading genome centres. Through its ability to conduct research at scale, it is able to engage in bold and long-term exploratory projects that are designed to influence and empower medical science globally. Institute research findings, generated through its own research programmes and through its leading role in international consortia, are being used to develop new diagnostics and treatments for human disease. http://www.sanger.ac.uk

The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. We support the brightest minds in biomedical research and the medical humanities. Our breadth of support includes public engagement, education and the application of research to improve health. We are independent of both political and commercial interests. http://www.wellcome.ac.uk

Contact details Don Powell Media Manager
Wellcome Trust Sanger Institute
Hinxton, Cambridge, CB10 1SA, UK
Tel +44 (0)1223 496 928
Mobile +44 (0)7753 7753 97
Email press.office@sanger.ac.uk

End of Notes to Editors

ELSE PRESS RELEASES FROM THIS DATE:

Giant 'balloon of magma' inflates under Santorini

2012-09-10

A new survey suggests that the chamber of molten rock beneath Santorini's volcano expanded 10-20 million cubic metres – up to 15 times the size of London's Olympic Stadium – between January 2011 and April 2012. The growth of this 'balloon' of magma has seen the surface of the island rise 8-14 centimetres during this period, a team led by Oxford University scientists has found. The results come from an expedition, funded by the UK's Natural Environment Research Council, which used satellite radar images and Global Positioning System receivers (GPS) that can detect movements ...

OHSU research helps explain why an AIDS vaccine has been so difficult to develop

2012-09-10

PORTLAND, Ore. — For decades, a successful HIV vaccine has been the Holy Grail for researchers around the globe. Yet despite years of research and millions of dollars of investment, that goal has still yet to be achieved. Recent research by Oregon Health & Science University scientists explains a decades-old mystery as to why slightly weakened versions of the monkey AIDS virus were able to prevent subsequent infection with the fully virulent strain, but were too risky for human use, and why severely compromised or completely inactivated versions of the virus were not effective ...

Large lung cancer study shows potential for more targeted therapies

2012-09-10

A nationwide consortium of scientists has reported the first comprehensive genetic analysis of squamous cell carcinoma of the lung, a common type of lung cancer responsible for about 400,000 deaths each year. "We found that almost 75 percent of the patients' cancers have mutations that can be targeted with existing drugs -- drugs that are available commercially or for clinical trials," says one of the lead investigators, Ramaswamy Govindan, MD, an oncologist at Washington University School of Medicine in St. Louis and co-chair of the lung cancer group of The Cancer Genome ...

Protecting genes, one molecule at a time

2012-09-10

An international team of scientists have shown at an unprecedented level of detail how cells prioritise the repair of genes containing potentially dangerous damage. The research, published in the journal Nature and involving academics from the University of Bristol, the Institut Jacques-Monod in France and Rockefeller University in the US, studied the action of individual molecules in order to understand how cellular repair pathways are triggered. The genetic information that forms the "instruction booklet" for cells is encoded in the molecular building blocks of DNA, ...

Nano-velcro clasps heavy metal molecules in its grips

2012-09-10

Mercury, when dumped in lakes and rivers, accumulates in fish, and often ends up on our plates. A Swiss-American team of researchers led by Francesco Stellacci at the Ecole Polytechnique Fédérale de Lausanne (EPFL) and Bartosz Grzybowski at Northwestern University has devised a simple, inexpensive system based on nanoparticles, a kind of nano-velcro, to detect and trap this toxic pollutant as well as others. The particles are covered with tiny hairs that can grab onto toxic heavy metals such as mercury and cadmium. This technology makes it possible to easily and inexpensively ...

UNC Lineberger scientists lead definition of key lung cancer genome

2012-09-10

In the September 9, 2012 early online edition of Nature, scientists with The Cancer Genome Atlas (TCGA) report that they have characterized the lung squamous cell carcinoma genome. Squamous cell carcinoma is the second most common form of lung cancer, a disease that kills more Americans than any other type of cancer. The national team of scientists examined tumor samples from 178 patients with untreated lung squamous cell carcinoma and completed genetic analysis of the tumors, work that paves the way for developing better, more targeted therapies to treat the cancer. ...

New potential targets discovered for treating squamous cell lung cancers

2012-09-10

Cambridge and Boston, MA. Sunday, September 9, 2012 – A new paper published online in Nature holds out hope that people with the second most common type of lung cancer may one day benefit from targeted therapies that have transformed treatments for other lung cancer patients. Squamous cell lung cancer kills more people each year than breast, colorectal, or prostate cancer, ranking second only to lung adenocarcinoma in the number of deaths it causes. But unlike the most common form of lung cancer, squamous cell carcinoma has no treatments aimed at the specific genetic ...

Research finds novel airborne germ-killing oral spray effective in fighting colds and flu

2012-09-10

University Hospitals Case Medical Center clinical researchers will present findings about a one-two punch to prevent colds and flu in San Francisco at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on Sept. 9. The research team is presenting data in two poster presentations that a new oral antiseptic spray is effective in killing 99.9 percent of infectious airborne germs. Findings from these two presentations led to the development of Halo Oral Antiseptic, a first-of-its kind germ-fighting spray which is currently on store shelves. "Respiratory ...

Wolf mange part of nature's cycle

2012-09-10

Mange and viral diseases have a substantial, recurring impact on the health and size of reintroduced wolf packs living in Yellowstone National Park, according to ecologists. Following the restoration of gray wolves to Yellowstone in 1996, researchers collected blood from the animals to monitor parasite-induced disease and death. They also tracked the wolves in each pack to follow their survival and allow additional data-gathering. "Many invasive species flourish because they lack their native predators and pathogens, but in Yellowstone we restored a native predator ...

Forest mortality and climate change: The big picture

2012-09-10

Washington, D.C.— Over the past two decades, extensive forest death triggered by hot and dry climatic conditions has been documented on every continent except Antarctica. Forest mortality due to drought and heat stress is expected to increase due to climate change. Although research has focused on isolated incidents of forest mortality, little is known about the potential effects of widespread forest die-offs. A new analysis of the current literature on this topic by Carnegie's William and Leander Anderegg is published September 9 in Nature Climate Change. Along with ...

Genetic clues to the causes of primary biliary cirrhosis!

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: